Date: 2011-12-20
Type of information:
Compound: DuoBody™ Platform
Company: Genmab (Denmark) - undisclosed pharma company
Therapeutic area: Cancer Oncology
Type agreement: R&D
Action mechanism:
Disease: solid tumors
Details: Genmab has entered a research collaboration with an as yet undisclosed, new large pharmaceutical partner to investigate a bispecific antibody-drug conjugate using Genmab’s DuoBody technology in combination with a novel antibody-drug conjugate technology platform from the pharma company. If successful, the parties may decide to enter into a license agreement to further develop a new DuoBody-ADC product. The target in the collaboration is clinically validated and expressed on solid tumors.
Financial terms:
Latest news:
